Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug MCI-196 tested for safety in dialysis patients with high phosphorus

NCT ID NCT00772382

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the long-term safety of a drug called MCI-196 (Colestilan) in 116 adults with stage 5 chronic kidney disease who are on dialysis and have high phosphorus levels. Participants took flexible doses of the drug for 52 weeks. The main goal was to see how many side effects occurred, and the study also checked if the drug helped lower phosphorus levels over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MCI-196 (also known as Colestilan or Colestimide), a drug taken as a tablet to lower phosphorus levels
What this could lead to
If successful, this could confirm MCI-196 as a safe long-term option to control phosphorus levels in dialysis patients, helping manage a common complication of kidney disease.
What could go wrong
This is a completed phase 3 trial, but it only looked at safety and basic effectiveness in 116 people. Results may not apply to all dialysis patients, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure hyperphosphatemia wild type ABeta2M amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE DIALYSIS HYPERPHOSPHATEMIA

Contacts and locations

Locations

  • Study site

    Los Angeles, California, United States

  • Study site

    Orange, California, United States

  • Study site

    Tarzana, California, United States

  • Study site

    Orlando, Florida, United States

  • Study site

    Pembroke Pines, Florida, United States

  • Study site

    Atlanta, Georgia, United States

  • Study site

    Gurnee, Illinois, United States

  • Study site

    Evansville, Indiana, United States

  • Study site

    Baton Rouge, Louisiana, United States

  • Study site

    New Orleans, Louisiana, United States

  • Study site

    Northport, New York, United States

  • Study site

    Durham, North Carolina, United States

  • Study site

    Oklahoma City, Oklahoma, United States

  • Study site

    Nashville, Tennessee, United States

  • Study site

    Houston, Texas, United States

  • Study site

    Burlington, Vermont, United States

  • Study site

    Chesapeake, Virginia, United States

  • Study site

    Kamloops, British Columbia, Canada

  • Study site

    London, Ontario, Canada

  • Study site

    Toronto, Ontario, Canada

  • Study site

    Montreal, Quebec, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.